(Q43210222)

16 November 2017

title

Effect of spironolactone on urinary protein excretion in patients with chronic kidney disease (English)

1 reference

16 November 2017

2

Tayfun Sahin

1 reference

16 November 2017

Erkan Sengul

1

1 reference

16 November 2017

Erce Sevin

series ordinal

3

1 reference

16 November 2017

Ahmet Yilmaz

series ordinal

4

1 reference

16 November 2017

publication date

1 January 2009

1 reference

16 November 2017

1 reference

16 November 2017

volume

31

1 reference

16 November 2017

issue

10

1 reference

16 November 2017

page(s)

928-932

1 reference

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

16 November 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F08860220903216121

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08860220903216121

Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08860220903216121

Aldosterone in the development and progression of renal injury

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08860220903216121

Aldosterone and end-organ damage

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08860220903216121

Effectiveness of aldosterone blockade in patients with diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08860220903216121

Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08860220903216121

Mineralocorticoid receptor antagonists: The evolution of utility and pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08860220903216121

Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08860220903216121

Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08860220903216121

Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08860220903216121

Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08860220903216121

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08860220903216121

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08860220903216121

Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08860220903216121

Hyperkalaemia and impaired renal function in patients taking spironolactone for congestive heart failure: retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08860220903216121

Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08860220903216121

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08860220903216121

10.3109/08860220903216121

21 January 2018

Identifiers

DOI

1 reference

16 November 2017

1 reference